Key Points
- Amgen SVP Rachna Khosla sold 2,000 shares at an average price of $412.57, generating $825,140 and reducing her direct ownership by 23.8%. She also recently sold an additional 1,252 shares.
- Amgen’s latest quarterly results exceeded expectations, with adjusted earnings of $6.29 per share and revenue of $10.05 billion, up 9.5% year over year. The company maintained fiscal 2026 guidance of $22.30–$23.50 in earnings per share.
- Shares were trading near a 12-month high at $417.84, while analysts maintained a consensus “Hold” rating with an average price target of $371.68. Amgen also announced a quarterly dividend of $2.52 per share, equating to a 2.4% yield.
Amgen Inc. (NASDAQ:AMGN - Get Free Report) SVP Rachna Khosla sold 1,252 shares of the business's stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the sale, the senior vice president owned 6,404 shares of the company's stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link.
Rachna Khosla also recently made the following trade(s):
- On Tuesday, August 11th, Rachna Khosla sold 2,000 shares of Amgen stock. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00.
Amgen Stock Up 0.4%
Amgen stock opened at $417.84 on Friday. The firm has a market capitalization of $225.90 billion, a price-to-earnings ratio of 25.97, a price-to-earnings-growth ratio of 3.87 and a beta of 0.41. The firm's fifty day moving average price is $369.26 and its two-hundred day moving average price is $358.53. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $421.79. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44.
Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the previous year, the firm posted $6.02 earnings per share. The firm's revenue for the quarter was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities research analysts predict that Amgen Inc. will post 22.78 earnings per share for the current fiscal year.
Amgen Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Friday, August 21st. Amgen's payout ratio is currently 62.65%.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on AMGN. The Goldman Sachs Group set a $389.00 target price on Amgen in a report on Friday, June 5th. Oppenheimer upped their price target on Amgen from $400.00 to $450.00 and gave the stock an "outperform" rating in a report on Wednesday, August 5th. BMO Capital Markets increased their price target on Amgen from $400.00 to $450.00 and gave the company an "outperform" rating in a research report on Wednesday, August 5th. Cantor Fitzgerald reissued a "neutral" rating and issued a $350.00 price target on shares of Amgen in a research report on Monday, July 6th. Finally, UBS Group raised their price objective on Amgen from $420.00 to $440.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $371.68.
Check Out Our Latest Research Report on AMGN
Hedge Funds Weigh In On Amgen
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Roman Butler Fullerton & Co. increased its position in shares of Amgen by 1.4% during the second quarter. Roman Butler Fullerton & Co. now owns 1,956 shares of the medical research company's stock valued at $705,000 after acquiring an additional 27 shares during the last quarter. High Note Wealth LLC grew its stake in Amgen by 5.8% in the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company's stock valued at $166,000 after purchasing an additional 28 shares during the period. TAGStone Capital Inc. increased its position in shares of Amgen by 0.7% during the 4th quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company's stock valued at $1,351,000 after purchasing an additional 28 shares during the last quarter. Verus Capital Partners LLC increased its position in shares of Amgen by 2.3% during the 4th quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company's stock valued at $403,000 after purchasing an additional 28 shares during the last quarter. Finally, Destination Wealth Management increased its position in shares of Amgen by 2.1% during the 4th quarter. Destination Wealth Management now owns 1,393 shares of the medical research company's stock valued at $456,000 after purchasing an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.
About Amgen
(
Get Free Report)
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
